IOP-Driven Expansion Myra Vision is developing a novel glaucoma treatment device focused on safe personalized intraocular pressure control, signaling opportunities to engage ophthalmology clinics, eye care providers, and medical device distributors seeking advanced IOP management solutions.

Series Growth Momentum With a $17M Series A in 2021 and a $25M Series B in 2023, plus ongoing first-in-human investigations, there is evident investor and clinical validation that can be leveraged to secure partnerships, pilot programs, and early adopter sites.

Manufacturing Scale Ready Funding to scale manufacturing capabilities indicates readiness to support early commercial rollouts; engage contract manufacturers, turnkey packaging partners, and supply chain integrators for scalable production.

Shifamed Backing As a privately held portfolio company of Shifamed LLC, Myra Vision may benefit from strategic collaboration channels, co-marketing opportunities, and broader ophthalmology distribution networks tied to Shifamed’s portfolio.

Clinical and Market Fit The Calibreye System and aqueous shunt development target moderate to advanced glaucoma, presenting a clear value proposition for specialty retina and glaucoma centers; explore pilot sites, reimbursement discussions, and key opinion leader engagement.